Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib
BiotechTV - News
00:00
Implications for trial design and intermittent dosing
Richard discusses extended follow-up, intermittent treatment strategies, and regulatory expectations.
Play episode from 09:41
Transcript
